5 completed, 1 recruiting, 1 suspended, 1 unknown. 3 Phase 1, 2 Not applicable, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 4 | 2 | Completed 1, Suspended 1 |
Follow Bendroflumethiazide: new trials by email Literature Review of Bendroflumethiazide trials Research Report on Bendroflumethiazide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mechanisms of Diuretic Resistance in Heart Failure, Aim 2 Placebo, Amiloride, Bendroflumethiazide - Heart Failure | Phase 1 | Recruiting | Yale University | 50 | 2023-08-10 | 2026-09-08 |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg, Corzide® Tablets 80 mg/5 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 42 | 2006-08-01 | 2024-04-23 |
| Double Blind Crossover Comparison of Diuretics in the Young Bendroflumethiazide 2.5mg - 5mg, Amiloride 20-40mg, Spironolactone 50-100mg - Low-Renin Hypertension | Not applicable | Unknown | University of Cambridge | 30 | 2006-08-01 | 2007-02-01 |
| Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg, Corzide® Tablets 80 mg/5 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 66 | 2006-07-01 | 2024-04-23 |
| Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD, Valsartan 160mg OD; Moxonidine 400mcg OD - Hypertension, Left Ventricular Hypertrophy | Not applicable | Completed | University of Leeds | 42 | 2003-09-01 | 2012-08-16 |
| A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients Lacidipine, Bendrofluazide, Placebo - Hypertension | Phase 4 | Completed | Boehringer Ingelheim | 26 | 1997-12-01 | 2014-09-10 |
Hypertension (5) · COVID-19 (1) · Cardiovascular Diseases (1) · Coronavirus Infections (1) · Heart Failure (1) · Hypertrophy, Left Ventricular (1)
Mylan Pharmaceuticals Inc (2) · Boehringer Ingelheim (1) · National University of Ireland, Galway, Ireland (1) · University of Cambridge (1) · University of Leeds (1) · University of Utah (1) · Yale University (1)
United States (4) · United Kingdom (2) · Ireland (1)
James D Carlson, Pharm. D. (2) · Adam P Bress, PharmD, MS (1) · Jeffrey Testani (1) · John P Greenwood, MBChB, PhD (1) · John William McEvoy, MBBCh MHS (1) · Morris J Brown, Proffessor (1)
R01DK130997 (1)